Significant Association between IL-17F Promoter Region Polymorphism and Susceptibility to Asthma in a Korean PopulationJin E.-H.a · Choi E.-Y.a · Yang J.Y.a · Chung H.-T.c · Yang Y.-S.a, b
aGenome Research Center for Immune Disorders and bDepartment of Ophthalmology, School of Medicine, Wonkwang University, Iksan, and cSchool of Biological Sciences, University of Ulsan, Ulsan, Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Individual differences in susceptibility to asthma would be expected because of common DNA variants of single nucleotide polymorphisms (SNPs) across populations. The pro-inflammatory cytokine IL-17F has homology with the IL-17 motif and induces the expression of other inflammatory cytokines in airway epithelial cells. This study aimed to identify IL-17F gene polymorphisms and to determine a possible association between these polymorphisms and susceptibility to asthma through a case-control study in a Korean population. Methods: We identified SNPs in the IL-17F gene by sequencing. Genotyping was conducted using the high-resolution melting (HRM) method on 424 asthma patients and 548 healthy controls. Results: The genotype and allele frequencies of rs1889570 SNP were significantly different between asthma patients and healthy controls (p = 0.001 and 0.002, respectively). The rs1889570 SNP genotype was also positively associated with the number of peripheral blood eosinophils in asthma patients (p = 0.03). The frequencies of haplotypes AA (p = 0.01), GG (p = 0.01) and AG (p = 0.006) were significantly different between asthma patients and healthy controls. Conclusions: In this study, we confirmed that the rs1889570 polymorphism of the IL-17F gene is associated with susceptibility to asthma in a Korean population.
© 2010 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.